Hookipa Biotech GmbH
8 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART (NCT06430905) | Hookipa Biotech GmbH | 2024-07-01 |
| Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma (NCT06771674) | Hookipa Biotech GmbH | 2024-06-05 |
| HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT05553639) | Hookipa Biotech GmbH | 2023-05-23 |
| A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (NCT04180215) | Hookipa Biotech GmbH | 2019-12-11 |
| A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients (NCT03629080) | Hookipa Biotech GmbH | 2018-12-12 |
Track Hookipa Biotech GmbH automatically
Every clearance here is in the API, with alerts when new ones post.